Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 6, 2009, Pages 825-829

  Cho, Young Ah ^a   Choi, Dong Hyun ^a   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

Author keywords

Diltiazem; Hesperidin; Pharmacokinetics; Rats

Indexed keywords

DEACETYLDILTIAZEM; DILTIAZEM; HESPERIDIN; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; MALE; METABOLITE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE; ANIMAL; BIOAVAILABILITY; DOSE RESPONSE; DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HESPERIDIN; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85047681574     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.06.0017     Document Type: Article

References (32)

1. Chaffman M, Brogden RN. Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29: 387-454.
2. Weir MR. Diltiazem: ten years of clinical experience in the treatment of hypertension. J Clin Pharmacol 1995; 35: 220-232.
3. Yeung PK et al. Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. Eur J Drug Metab Pharmacokinet 1993; 18: 199-206.
4. Buckley MMT et al. Diltiazem: a reappraisal of its pharmacological properties and therapeutic use. Drugs 1990; 39: 757-806.
5. Narita H et al. Hypotensive response of spontaneously hypertensive rats to centrally administered diltiazem and its metabolites: in relevance to the hypotensive action by oral administration. J Pharmacobiodyn 1986; 9: 547-553.
6. Yeung PK et al. Pharmacokinetics and hypotensive effect of diltiazem in rabbits: comparison of diltiazem with its major metabolites. J Pharm Pharmacol 1998; 50: 1247-1253.
7. PichardLGet al. Identificationof the rabbit andhumancytochromes P-450IIIAas themajor enzymes involved in theN-demethylation of diltiazem. Drug Metab Dispos 1990; 18: 711-719.
8. Watkins PB et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-1036.
9. Kolars JC et al. Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 1992; 102: 1186-1198.
10. Lefebvre M et al. First-pass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs. Pharm Res 1996; 13: 124-128.
11. Homsy W et al. The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm Res 1995; 12: 1722-1726.
12. Homsy W et al. Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies. Pharm Res 1995; 12: 609-614.
13. Lee YH et al. Pharmacokinetics of diltiazem and deacetyldiltiazem in rats. Int J Pharm 1991; 76: 71-76.
14. Wacher VJ et al. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001; 46: 89-102.
15. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
16. Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000; 22: 131-136.
17. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32: 451-478.
18. Zhou S et al. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104.
19. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002; 22: 19-34.
20. Hodek P et al. Flavonoids - potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002; 139: 1-21.
21. Tsai TH, Liu MC. Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 806: 161-166.
22. Fuhr U et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 2002; 58: 45-53.
23. Mitsunaga Y et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000; 395: 193-201.
24. Yeung PKF et al. Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits, and rats. Drug Metab Dispos 1990; 18: 1055-1059.
25. Goebel KJ, Kolle EU. High performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. J Chromatogr 1985; 345: 355-363.
26. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304: 1258-1267.
27. Bobrowska-Hagerstrand M et al. Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol Res 2003; 13: 463-469.
28. Molden E et al. Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. Drug Metab Dispos 2002; 30: 1-3.
29. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989; 49: 5002-5006.
30. Saeki T et al. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett 1993; 324: 99-102.
31. Piao YJ, Choi JS. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res 2008; 31: 528-533.
32. Choi JS, Han HK. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol Res 2005; 52: 386-391.